Literature DB >> 20732764

Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy.

Cheng Peng1, Ergun Ahunbay, Guangpei Chen, Savannah Anderson, Colleen Lawton, X Allen Li.   

Abstract

PURPOSE: To quantitatively characterize the interfraction variations and their dosimetric effects in radiotherapy for prostate cancer. METHODS AND MATERIALS: A total of 486 daily computed tomography (CT) sets acquired for 20 prostate cancer patients treated with daily CT-guided repositioning using a linear accelerator and CT-on-rail combination were analyzed. The prostate, rectum, and bladder, delineated on each daily CT data set, were compared with those from the planning CT scan. Several quantities, including Dice's coefficient and the maximal overlapping rate, were used to characterize the interfraction variations. The delivered dose was reconstructed by applying the original plan to the daily CT scan with consideration of proper repositioning.
RESULTS: The mean prostate Dice's coefficient and maximal overlapping rate after bony registration was 69.7%±13.8% (standard deviation) and 85.6%±7.8% (standard deviation), respectively. The daily delivered dose distributions were generally inferior to the planned dose distribution for target coverage and/or normal structure sparing. For example, for approximately 5% of the treatment fractions, the prostate volume receiving 100% of the prescription dose decreased dramatically (15-20%) compared with its planned value. The magnitudes of the interfraction variations and their dosimetric effects indicated that, statistically, current standard repositioning using prostate alignment might be adequate for two-thirds of the fractions, but for the rest of the fractions, better on-line correction strategies, such as on-line replanning, are needed.
CONCLUSION: Different adaptive correction schemes for prostatic interfraction changes can be used according to the anatomic changes, as quantified by the organ displacement and deformation parameters. On-line replanning is needed for approximately one-third of the treatment fractions.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20732764     DOI: 10.1016/j.ijrobp.2010.05.008

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  28 in total

Review 1.  Evolution of advanced technologies in prostate cancer radiotherapy.

Authors:  Nicholas G Zaorsky; Amy S Harrison; Edouard J Trabulsi; Leonard G Gomella; Timothy N Showalter; Mark D Hurwitz; Adam P Dicker; Robert B Den
Journal:  Nat Rev Urol       Date:  2013-09-10       Impact factor: 14.432

2.  Comparison of MRI visualization between linearly placed iron-containing and non-iron-containing fiducial markers for prostate radiotherapy.

Authors:  Osamu Tanaka; Hisao Komeda; Masayoshi Tamaki; Kensaku Seike; Shota Fujimoto; Eiichi Yama; Shigeki Hirose; Masayuki Matsuo
Journal:  Br J Radiol       Date:  2017-11-28       Impact factor: 3.039

3.  Determination of action thresholds for electromagnetic tracking system-guided hypofractionated prostate radiotherapy using volumetric modulated arc therapy.

Authors:  Pengpeng Zhang; Dennis Mah; Laura Happersett; Brett Cox; Margie Hunt; Gig Mageras
Journal:  Med Phys       Date:  2011-07       Impact factor: 4.071

4.  Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer.

Authors:  Michael Wahl; Martina Descovich; Erin Shugard; Dilini Pinnaduwage; Atchar Sudhyadhom; Albert Chang; Mack Roach; Alexander Gottschalk; Josephine Chen
Journal:  Technol Cancer Res Treat       Date:  2016-07-08

5.  Scanned ion beam therapy for prostate carcinoma: Comparison of single plan treatment and daily plan-adapted treatment.

Authors:  Sebastian Hild; Christian Graeff; Antoni Rucinski; Klemens Zink; Gregor Habl; Marco Durante; Klaus Herfarth; Christoph Bert
Journal:  Strahlenther Onkol       Date:  2015-11-27       Impact factor: 3.621

6.  Dose deformation-invariance in adaptive prostate radiation therapy: implication for treatment simulations.

Authors:  Manju Sharma; Elisabeth Weiss; Jeffrey V Siebers
Journal:  Radiother Oncol       Date:  2012-11-29       Impact factor: 6.280

7.  Coverage-based treatment planning to accommodate deformable organ variations in prostate cancer treatment.

Authors:  Huijun Xu; Douglas J Vile; Manju Sharma; J James Gordon; Jeffrey V Siebers
Journal:  Med Phys       Date:  2014-10       Impact factor: 4.071

Review 8.  Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment.

Authors:  J E Scaife; G C Barnett; D J Noble; R Jena; S J Thomas; C M L West; N G Burnet
Journal:  Br J Radiol       Date:  2015-05-26       Impact factor: 3.039

9.  Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity.

Authors:  Gamze Ugurluer; Banu Atalar; Teuta Zoto Mustafayev; Gorkem Gungor; Gokhan Aydin; Meric Sengoz; Ufuk Abacioglu; Mustafa Bilal Tuna; Ali Riza Kural; Enis Ozyar
Journal:  Br J Radiol       Date:  2020-10-29       Impact factor: 3.039

10.  Commissioning of and preliminary experience with a new fully integrated computed tomography linac.

Authors:  Lei Yu; Jun Zhao; Zhen Zhang; Jiazhou Wang; Weigang Hu
Journal:  J Appl Clin Med Phys       Date:  2021-06-20       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.